Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01993810 · ClinicalTrials.gov registry record · Phase 3

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

A Phase 3 study of Stage II Non-Small Cell Lung Cancer AJCC v7 and Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, sponsored by Radiation Therapy Oncology Group.

Active
Registry status
Phase 3
Development phase
330
Enrollment target
20
Study locations

NCT01993810 is a Phase 3 study of Stage II Non-Small Cell Lung Cancer AJCC v7 and Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 that is active but no longer recruiting, run by Radiation Therapy Oncology Group. The registered enrollment target is 330 participants, above the 111-participant average among 3 other Stage II Non-Small Cell Lung Cancer AJCC v7 trials with a reported enrollment target (197% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01993810, a Phase 3 study of Stage II Non-Small Cell Lung Cancer AJCC v7 and Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, is active but no longer recruiting, sponsored by Radiation Therapy Oncology Group.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
330 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.

Conditions Studied

Stage II Non-Small Cell Lung Cancer AJCC v7 Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Non-Small Cell Lung Cancer AJCC v7 Stage III Non-Small Cell Lung Cancer AJCC v7

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • BIOLOGICAL Durvalumab
  • DRUG Paclitaxel
  • DRUG Etoposide

Study Locations (20)

Maryland

  • Maryland Proton Treatment Center - Baltimore
  • University of Maryland/Greenebaum Cancer Center - Baltimore
  • Upper Chesapeake Medical Center - Bel Air
  • Central Maryland Radiation Oncology in Howard County - Columbia
  • Tate Cancer Center - Glen Burnie

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Rockville Centre - Rockville Centre
  • Memorial Sloan Kettering Sleepy Hollow - Sleepy Hollow

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Mass General/North Shore Cancer Center - Danvers

Missouri

  • Siteman Cancer Center at West County Hospital - Creve Coeur
  • Washington University School of Medicine - St Louis

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • ProCure Proton Therapy Center-Somerset - Somerset

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • West Chester Hospital - West Chester

Florida

  • University of Florida Health Science Center - Jacksonville - Jacksonville

Illinois

  • Northwestern Medicine Cancer Center Warrenville - Warrenville

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2014-02-03
Est. Completion 2028-10
Phase Phase 3

Sponsor

Radiation Therapy Oncology Group

144 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01993810

The ClinicalTrials.gov registry entry for NCT01993810 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 111-participant average among 3 other Stage II Non-Small Cell Lung Cancer AJCC v7 trials with a reported enrollment target (197% higher). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Stage II Non-Small Cell Lung Cancer AJCC v7 appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT01993810 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Maryland, New York, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01993810 about?

NCT01993810 is a clinical study titled "Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer". This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation di...

What is the current status of trial NCT01993810?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2014-02-03. Estimated completion is 2028-10.

What conditions does trial NCT01993810 study?

This clinical trial studies the following conditions: Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7.

What interventions are being tested in trial NCT01993810?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Durvalumab (BIOLOGICAL), Paclitaxel (DRUG), Etoposide (DRUG).

Who is sponsoring clinical trial NCT01993810?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01993810 being conducted?

This trial has 20 study locations across Florida, Illinois, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage II Non-Small Cell Lung Cancer AJCC v7

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage II Non-Small Cell Lung Cancer AJCC v7

All registered trials for this condition

Stage IIA Non-Small Cell Lung Carcinoma AJCC v7

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.